臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"zhong zhe lin"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 91-115 / 125 (共5頁)
<< < 1 2 3 4 5 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-08-11T03:46:46Z	Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma	Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; ZHONG-ZHE LIN; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:46Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	ZHONG-ZHE LIN; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏	2021-08-11T03:46:45Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:45Z	Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study	ZHONG-ZHE LIN; Shau W.-Y.; Shao Y.-Y.; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S.
臺大學術典藏	2021-08-11T03:46:44Z	The aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme	Lee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F.
臺大學術典藏	2021-08-11T03:46:44Z	Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer	Shao Y.-Y.; Shau W.-Y.; ZHONG-ZHE LIN; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:43Z	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy	Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN
臺大學術典藏	2021-08-11T03:46:43Z	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma	Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; ZHONG-ZHE LIN; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:43Z	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size	ZHONG-ZHE LIN; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:42Z	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma	Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:42Z	Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer	Chen K.-H.; Shao Y.-Y.; ZHONG-ZHE LIN; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:42Z	Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer	Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:41Z	Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption	ZHONG-ZHE LIN; Chou C.-H.; Cheng A.-L.; Liu W.-L.; Chia-Hsien Cheng J.
臺大學術典藏	2021-08-11T03:46:41Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	Kuo H.-Y.; ZHONG-ZHE LIN; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:41Z	Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma	Liao B.-C.; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:40Z	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan	Shao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:40Z	Young patients with colorectal cancer have increased risk of second primary cancers	Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; ZHONG-ZHE LIN; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S.
臺大學術典藏	2021-08-11T03:46:39Z	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)	Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.
臺大學術典藏	2021-08-11T03:46:39Z	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study	Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN; Lai M.-S.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏	2021-08-11T03:46:39Z	The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases	Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; ZHONG-ZHE LIN; Lan K.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏	2021-08-11T03:46:38Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J.
臺大學術典藏	2021-08-11T03:46:38Z	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma	Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏	2021-08-11T03:46:38Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏	2021-08-11T03:46:37Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:37Z	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients	Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.-H.; Yu C.-J.

顯示項目 91-115 / 125 (共5頁)
<< < 1 2 3 4 5 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 51843403 線上人數 : 1103 教育部委託研究計畫計畫執行:國立臺灣大學圖書館